Precision Biosciences (DTIL) Consolidated Net Income (2018 - 2026)
Precision Biosciences (DTIL) reported Consolidated Net Income of -$8.4 million for Q1 2026, up 60.33% year-over-year from -$5.2 million in Q1 2025, and down 164.85% quarter-over-quarter from $12.9 million in Q4 2025.
Precision Biosciences (DTIL) Consolidated Net Income (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Consolidated Net Income data on file, last reported at -$8.4 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$8.4 million, up 60.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$36.6 million (up 6.76% YoY), and the FY2025 annual result was $885000.0, changed N/A from the prior year.
- Consolidated Net Income fell to -$8.4 million in Q1 2026 per DTIL's latest filing, from $12.9 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $25.4 million in Q2 2024 and troughed at -$29.5 million in Q2 2022.
- A 5-year average of -$10.1 million and a median of -$9.1 million in 2022 frame the typical range for Consolidated Net Income.
- On a YoY basis, Consolidated Net Income climbed as much as 387.07% in 2024 and fell as far as 731.66% in 2024.
- A 5-year view of Consolidated Net Income shows it stood at -$9.1 million in 2022, then soared by 68.49% to -$2.9 million in 2023, then plunged by 731.66% to -$23.7 million in 2024, then soared by 154.47% to $12.9 million in 2025, then plunged by 164.85% to -$8.4 million in 2026.
- Business Quant data shows DTIL's Consolidated Net Income at -$8.4 million in Q1 2026, $12.9 million in Q4 2025, and -$20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Precision Biosciences | 150.27 Mn | 49.09 Mn | - | -8.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.39 Mn |
| Dec 31, 2025 | 12.93 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -21.12 Mn |
| Mar 31, 2025 | -21.14 Mn |
| Dec 31, 2024 | -23.74 Mn |
| Sep 30, 2024 | -19.77 Mn |
| Jun 30, 2024 | 25.43 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -2.86 Mn |
| Sep 30, 2023 | 4.03 Mn |
| Jun 30, 2023 | -8.86 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -9.06 Mn |
| Sep 30, 2022 | -8.26 Mn |
| Jun 30, 2022 | -29.54 Mn |
| Mar 31, 2022 | -27.21 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -11.55 Mn |
| Jun 30, 2021 | 21.66 Mn |